# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy rating and ann...
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate...
B. Riley Securities analyst Kyle Bauser initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy rating and ann...
Chardan Capital analyst Keay Nakae reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate o...
Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate o...
New pharmacokinetic data demonstrate Virtue® SAB enables extended release of sirolimus above required tissue concentrations i...